paper_id,claim,figure_id,title,caption,local_image_path,url
PMC6064585,Patients underwent 16 weeks of open-label treatment with the nearest multiple of metformin IR 500 mg to their usual dose and dapagliflozin 10 mg/day (Fig. 1).,PMC6064585_figure_1,Fig. 1.,"Design for the lead-in periods of the sequential add-on triple therapy studies. DAPA dapagliflozin, HbA1c glycated hemoglobin, IR immediate release, MET metformin, SAXA saxagliptin",./data/PMC6064585/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg
PMC6064585,Patients received the nearest multiple of metformin IR 500 mg to their usual dose and saxagliptin 5 mg/day for 16 weeks of open-label treatment (Fig. 1).,PMC6064585_figure_1,Fig. 1.,"Design for the lead-in periods of the sequential add-on triple therapy studies. DAPA dapagliflozin, HbA1c glycated hemoglobin, IR immediate release, MET metformin, SAXA saxagliptin",./data/PMC6064585/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg
PMC6064585,"Efficacy
The mean change in HbA1c [95% confidence interval (CI)] from lead-in baseline to end of lead-in was − 1.6% (− 1.7, − 1.5) [− 17.5 mmol/mol (− 18.6, − 16.4)] in patients in study 1 receiving dapagliflozin plus metformin therapy (Fig. 2).",PMC6064585_figure_2,Fig. 2.,"HbA1c levels at lead-in baseline and the end of the lead-in period. Efficacy end points were assessed at week − 2 before randomization (treatment duration 14 weeks). Data are mean with SD shown as error bars. Mean change from baseline (95% CI) is shown above the bars. n is the number of patients with baseline and week − 2 results. CI confidence interval, DAPA dapagliflozin, HbA1c glycated hemoglobin, MET metformin, SAXA saxagliptin, SD standard deviation",./data/PMC6064585/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg
PMC6064585,"In patients in study 2 receiving saxagliptin plus metformin therapy, the mean change in HbA1c from lead-in baseline to end of lead-in was − 1.3% (− 1.5, − 1.2) [− 14.2 mmol/mol (− 16.4, − 13.1)] (Fig. 2).",PMC6064585_figure_2,Fig. 2.,"HbA1c levels at lead-in baseline and the end of the lead-in period. Efficacy end points were assessed at week − 2 before randomization (treatment duration 14 weeks). Data are mean with SD shown as error bars. Mean change from baseline (95% CI) is shown above the bars. n is the number of patients with baseline and week − 2 results. CI confidence interval, DAPA dapagliflozin, HbA1c glycated hemoglobin, MET metformin, SAXA saxagliptin, SD standard deviation",./data/PMC6064585/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg
PMC6064585,"The mean change in HbA1c [95% confidence interval (CI)] from lead-in baseline to end of lead-in was − 1.6% (− 1.7, − 1.5) [− 17.5 mmol/mol (− 18.6, − 16.4)] in patients in study 1 receiving dapagliflozin plus metformin therapy (Fig. 2).",PMC6064585_figure_2,Fig. 2.,"HbA1c levels at lead-in baseline and the end of the lead-in period. Efficacy end points were assessed at week − 2 before randomization (treatment duration 14 weeks). Data are mean with SD shown as error bars. Mean change from baseline (95% CI) is shown above the bars. n is the number of patients with baseline and week − 2 results. CI confidence interval, DAPA dapagliflozin, HbA1c glycated hemoglobin, MET metformin, SAXA saxagliptin, SD standard deviation",./data/PMC6064585/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg
